143 related articles for article (PubMed ID: 21617728)
21. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
[TBL] [Abstract][Full Text] [Related]
22. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
23. Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome.
Jose J; Saravu K; Shastry BA
Am J Health Syst Pharm; 2007 Apr; 64(7):726-9. PubMed ID: 17384358
[TBL] [Abstract][Full Text] [Related]
24. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
[No Abstract] [Full Text] [Related]
25. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.
Wenisch C; Krause R; Fladerer P; El Menjawi I; Pohanka E
Am J Med; 2000 Jul; 109(1):78. PubMed ID: 10991749
[No Abstract] [Full Text] [Related]
26. Letter by Rosenberg and Uretsky regarding article, "Risks associated with statin therapy: a systematic overview of randomized clinical trials".
Rosenberg L; Uretsky S
Circulation; 2007 Jul; 116(1):e8; author reply e9. PubMed ID: 17606852
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
[TBL] [Abstract][Full Text] [Related]
28. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Maltz HC; Balog DL; Cheigh JS
Ann Pharmacother; 1999 Nov; 33(11):1176-9. PubMed ID: 10573315
[TBL] [Abstract][Full Text] [Related]
29. Statin-associated acute interstitial nephritis and rhabdomyolysis.
Panchangam V
Saudi J Kidney Dis Transpl; 2014 May; 25(3):659-60. PubMed ID: 24821172
[No Abstract] [Full Text] [Related]
30. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.
Mah Ming JB; Gill MJ
AIDS Patient Care STDS; 2003 May; 17(5):207-10. PubMed ID: 12816614
[TBL] [Abstract][Full Text] [Related]
33. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J; Judson I
Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
[TBL] [Abstract][Full Text] [Related]
34. Rhabdomyolysis with concurrent atorvastatin and diltiazem.
Lewin JJ; Nappi JM; Taylor MH
Ann Pharmacother; 2002 Oct; 36(10):1546-9. PubMed ID: 12243603
[TBL] [Abstract][Full Text] [Related]
35. A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis.
Noordally SO; Sohawon S; Vanderhulst J; Duttmann R; Corazza F; Devriendt J
Ann Saudi Med; 2012; 32(3):309-11. PubMed ID: 22588445
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs.
Crook MA
Ann Clin Biochem; 2011 Jan; 48(Pt 1):3-4. PubMed ID: 21273636
[No Abstract] [Full Text] [Related]
37. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
[TBL] [Abstract][Full Text] [Related]
38. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Salvatore E; Morra VB; Orefice G
Neurology; 2009 Sep; 73(13):1078; author reply 1078-9. PubMed ID: 19786703
[No Abstract] [Full Text] [Related]
39. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
[TBL] [Abstract][Full Text] [Related]
40. Statin adverse effects: sorting out the evidence.
Mlodinow SG; Onysko MK; Vandiver JW; Hunter ML; Mahvan TD
J Fam Pract; 2014 Sep; 63(9):497-506. PubMed ID: 25353029
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
